A sampling of global guidelines on the use of genomic biomarkers in drug development.
You may also be interested in...
Success rates are higher for clinical trials that incorporate selective pharmacogenomics and pharmacogenetics (PGX) biomarkers, according to data from Informa's Trialtrove. Given the challenges of designing and administering trials to secure regulatory approval in areas of unmet medical need, the data provide some basis for optimism in realizing the promise of targeted, personalized therapies that improve health outcomes for individual patients.
Informa Pharma Intelligence pays tribute to the people driving the advances in drug development and their commitments to advancing human health with the third annual CARE Awards.